CO2020006253A2 - Análogos de incretina y sus usos - Google Patents

Análogos de incretina y sus usos

Info

Publication number
CO2020006253A2
CO2020006253A2 CONC2020/0006253A CO2020006253A CO2020006253A2 CO 2020006253 A2 CO2020006253 A2 CO 2020006253A2 CO 2020006253 A CO2020006253 A CO 2020006253A CO 2020006253 A2 CO2020006253 A2 CO 2020006253A2
Authority
CO
Colombia
Prior art keywords
incretin analogs
activity
receptors
incretin
analogs
Prior art date
Application number
CONC2020/0006253A
Other languages
English (en)
Inventor
Tamer Coskun
Hongchang Qu
Jorge Alsina-Fernandez
Lili Guo
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO2020006253A2 publication Critical patent/CO2020006253A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Details Of Garments (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan análogos de incretina que tienen actividad en cada uno de los receptores GIP, GLP-1 y glucagón. Los análogos de incretina tienen características estructurales que dan como resultado una actividad equilibrada y una duración de acción extendida en cada uno de estos receptores. También se proporcionan métodos para tratar enfermedades tales como diabetes mellitus, dislipidemia, hepatopatía grasa, síndrome metabólico, esteatohepatitis no alcohólica y obesidad.
CONC2020/0006253A 2017-12-21 2020-05-22 Análogos de incretina y sus usos CO2020006253A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762608644P 2017-12-21 2017-12-21
PCT/US2018/065605 WO2019125929A1 (en) 2017-12-21 2018-12-14 Incretin analogs and uses thereof

Publications (1)

Publication Number Publication Date
CO2020006253A2 true CO2020006253A2 (es) 2020-05-29

Family

ID=65003515

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0006253A CO2020006253A2 (es) 2017-12-21 2020-05-22 Análogos de incretina y sus usos

Country Status (24)

Country Link
US (1) US11834486B2 (es)
EP (1) EP3727425A1 (es)
JP (2) JP6987993B2 (es)
KR (1) KR102440323B1 (es)
CN (1) CN111511387A (es)
AR (1) AR113487A1 (es)
AU (1) AU2018388895B2 (es)
BR (1) BR112020010410A2 (es)
CA (1) CA3084004C (es)
CL (1) CL2020001636A1 (es)
CO (1) CO2020006253A2 (es)
CR (1) CR20200256A (es)
DO (1) DOP2020000124A (es)
EA (1) EA202091284A1 (es)
EC (1) ECSP20032306A (es)
IL (1) IL275469A (es)
JO (1) JOP20200136A1 (es)
MA (1) MA51287A (es)
MX (1) MX2020006547A (es)
PH (1) PH12020551024A1 (es)
SG (1) SG11202004359YA (es)
TW (2) TWI810937B (es)
UA (1) UA127589C2 (es)
WO (1) WO2019125929A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI809515B (zh) * 2017-12-21 2023-07-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
TWI810937B (zh) * 2017-12-21 2023-08-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
KR20210031533A (ko) * 2018-07-23 2021-03-19 일라이 릴리 앤드 캄파니 Gip/glp1 공효능제 화합물
AR119471A1 (es) * 2019-08-01 2021-12-22 Lilly Co Eli Compuestos agonistas de gipr
AU2020334993B2 (en) * 2019-08-19 2023-07-13 Eli Lilly And Company Methods of making incretin analogs
TWI795698B (zh) * 2019-12-18 2023-03-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
CA3165430A1 (en) * 2020-01-23 2021-07-29 Jorge Alsina-Fernandez Gip/glp1 co-agonist compounds
TW202220700A (zh) * 2020-08-14 2022-06-01 南韓商韓美藥品股份有限公司 包含三重升糖素／ｇｌｐ－１／ｇｉｐ受體促效劑的長效接合物的醫藥組成物
WO2022090447A1 (en) 2020-10-30 2022-05-05 Novo Nordisk A/S Glp-1, gip and glucagon receptor triple agonists
AR125086A1 (es) 2021-03-23 2023-06-07 Lilly Co Eli Composiciones que contienen análogos de incretina y usos de estas
CA3219647A1 (en) 2021-05-26 2022-12-01 The United Bio-Technology (Hengqin) Co., Ltd. Multi agonists and use thereof
CN115572326A (zh) * 2021-06-21 2023-01-06 广东东阳光药业有限公司 Glp-1、gcg和gip受体的三重激动剂
EP4358994A1 (en) 2021-06-23 2024-05-01 Eli Lilly and Company An incretin analog for use in glycemic control and weight management
WO2023088140A1 (zh) * 2021-11-19 2023-05-25 南京明德新药研发有限公司 订合肽及其应用
CN116162147B (zh) * 2021-11-24 2023-10-03 成都奥达生物科技有限公司 一种长效胰岛素类似物
WO2024067662A1 (zh) * 2022-09-28 2024-04-04 广东东阳光药业股份有限公司 Glp-1/gcg/gip三受体激动剂及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1013588A2 (pt) 2009-03-27 2016-04-19 Glaxo Group Ltd composição
AR092873A1 (es) * 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
TR201902516T4 (tr) 2013-11-06 2019-03-21 Zealand Pharma As Glukagon-glp-1-gıp üçlü agonist bileşikleri.
KR102310389B1 (ko) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 Ｇｉｐ-ｇｌｐ-1 이원 효능제 화합물 및 방법
JOP20200119A1 (ar) 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
TWI783244B (zh) 2015-06-22 2022-11-11 美商美國禮來大藥廠 升糖素及glp-1共激動劑化合物
HRP20220995T1 (hr) 2015-12-31 2022-11-11 Hanmi Pharm. Co., Ltd. Trostruki aktivator koji aktivira glukagonski, glp-1 i gip receptore
EP3217027A1 (de) 2016-03-08 2017-09-13 HILTI Aktiengesellschaft Breites einlageelement zum einfassen einer ankerstange
TWI810937B (zh) * 2017-12-21 2023-08-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途

Also Published As

Publication number Publication date
JOP20200136A1 (ar) 2022-10-30
KR20200088418A (ko) 2020-07-22
EP3727425A1 (en) 2020-10-28
TW201938187A (zh) 2019-10-01
US20210221865A1 (en) 2021-07-22
ECSP20032306A (es) 2020-07-31
BR112020010410A2 (pt) 2020-11-24
SG11202004359YA (en) 2020-06-29
TWI810937B (zh) 2023-08-01
JP2022043082A (ja) 2022-03-15
PH12020551024A1 (en) 2021-05-31
AR113487A1 (es) 2020-05-06
CA3084004A1 (en) 2019-06-27
CN111511387A (zh) 2020-08-07
TW202233227A (zh) 2022-09-01
IL275469A (en) 2020-08-31
AU2018388895A1 (en) 2020-06-04
US11834486B2 (en) 2023-12-05
UA127589C2 (uk) 2023-10-25
MX2020006547A (es) 2020-12-09
AU2018388895B2 (en) 2020-12-24
JP6987993B2 (ja) 2022-01-05
JP2021506825A (ja) 2021-02-22
MA51287A (fr) 2021-03-31
TWI767095B (zh) 2022-06-11
DOP2020000124A (es) 2020-08-31
CA3084004C (en) 2023-06-20
CL2020001636A1 (es) 2020-10-16
WO2019125929A1 (en) 2019-06-27
EA202091284A1 (ru) 2020-09-08
CR20200256A (es) 2020-07-12
KR102440323B1 (ko) 2022-09-05

Similar Documents

Publication Publication Date Title
CL2020001635A1 (es) Análogos de incretina y sus usos.
CO2020006253A2 (es) Análogos de incretina y sus usos
CO2017000506A2 (es) Receptor quimérico de antígeno cll-1
CO2017001573A2 (es) Receptor quimérico de antígeno anti-cd123
IL268702B (en) Use of a long-acting dual glp-1/glucagon receptor agonist for the treatment of non-alcoholic fatty liver disease
CL2018001522A1 (es) Focalización de péptidos para dirigir virus adenoasociados (aavs)
CO2017000510A2 (es) Constructos de car
AR109625A1 (es) Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas
DOP2016000295A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
SV2017005486A (es) Anticuerpos a tau y usos de los mismos
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
DK3234107T3 (da) B-celler til in vivo-levering af terapeutiske midler
DOP2022000122A (es) Analogos de incretina y sus usos
AR101592A1 (es) Tratamiento de cáncer usando un receptor quimérico de antígeno cd123
AR112904A1 (es) Proteínas de unión a antígenos anti-gitr y métodos para el uso de las mismas